Scalable Synthesis and Cancer Cell Cytotoxicity of Rooperol and Analogues
-
Published:2022-03-09
Issue:6
Volume:27
Page:1792
-
ISSN:1420-3049
-
Container-title:Molecules
-
language:en
-
Short-container-title:Molecules
Author:
Schwartz Zachary,Theisen Peter,Bjornstal Olaf,Rodebaugh Mary,Jemal Mauricio,Lee Dallas,Shelton Spencer,Zhao Zhenze,Du Liqin,Kerwin Sean
Abstract
Plant polyphenols, such as the African potato (Hypoxis hemerocallidea)-derived bis-catechol rooperol, can display promising anticancer activity yet suffer from rapid metabolism. Embarking upon a program to systematically examine potentially more metabolically stable replacements for the catechol rings in rooperol, we report here a general, scalable synthesis of rooperol and analogues that builds on our previous synthetic approach incorporating a key Pd-catalyzed decarboxylative coupling strategy. Using this approach, we have prepared and evaluated the cancer cell cytotoxicity of rooperol and a series of analogues. While none of the analogues examined here were superior to rooperol in preventing the growth of cancer cells, analogues containing phenol or methylenedioxyphenyl replacements for one or both catechol rings were nearly as effective as rooperol.
Funder
National Science Foundation
Owens Medical Research Foundation
Subject
Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science
Reference33 articles.
1. African potato (Hypoxis hemerocallidea): a systematic review of its chemistry, pharmacology and ethno medicinal properties
2. Morphological Characterization of the Cell-Growth Inhibitory Activity of Rooperol and Pharmacokinetic Aspects of Hypoxoside as an Oral Prodrug for Cancer-Therapy;Albrecht;S. Afr. Med. J.,1995
3. Cell Survival or Apoptosis: Rooperol's Role as Anticancer Agent
4. Selective ROS-dependent p53-associated anticancer effects of the hypoxoside derivative rooperol on human teratocarcinomal cancer stem-like cells
5. The Pharmacokinetic Behavior of Hypoxoside Taken Orally by Patients with Lung-Cancer in a Phase-I Trial;Albrecht;S. Afr. Med. J.,1995